M&A Deal Summary

ArchiMed Acquires Bomi Group

On March 1, 2019, private equity firm ArchiMed acquired healthcare services company Bomi Group for 70M EUR

Acquisition Highlights
  • This is ArchiMed’s 3rd transaction in the Healthcare Services sector.
  • This is ArchiMed’s 2nd largest (disclosed) transaction.
  • This is ArchiMed’s 3rd transaction in Italy.
Investment Fate
  • Bomi Group was sold to a publicly-traded strategic buyer in 2022.

M&A Deal Summary
Date 2019-03-01
Target Bomi Group
Sector Healthcare Services
Buyer(s) ArchiMed
Deal Type Going Private
Deal Value 70M EUR
Advisor(s) Simmons & Simmons LLP (Legal)

Target

Bomi Group

Spino d’Adda, Italy
website
Bomi Group runs cutting-edge transport, warehousing, and supply chain management services for healthcare companies ranging from pharmaceutical and medical equipment manufacturers to hospitals, testing laboratories, and outpatient service providers. Bomi Group was formed in `1985 and is based in Spino d’Adda, Italy.

Search 192,611 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

ArchiMed

Investor Investor Investor Investor Investor

website

Category Private Equity Firm
Founded 2014
Size Middle-Market
Type Sector Focused
DESCRIPTION

ArchiMed is a specialist French private equity firm focused on buyouts of and growth capital investments in European healthcare-oriented companies. The Firm looks to invest €5 to €300 million per transaction and specifically targets companies in the public health, care and wellness, biotech, and medical technology segments of the healthcare industry. ArchiMed was formed in 2014 and is headquartered in Lyon.

DEAL STATS #
Overall 13 of 26
Sector (Healthcare Services) 3 of 3
Type (Going Private) 1 of 2
Country (Italy) 3 of 4
Year (2019) 1 of 3
Size (of disclosed) 2 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-11-22 Clean Cells

Bouffere, France

Clean Biologics is a biopharmaceutical services company specialized in the viral and biological safety of biopharmaceuticals including recombinant proteins, therapeutic antibodies, vaccines, cell and gene therapies, and phage therapy.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-07-09 Eurolyser

Salzburg, Austria

Eurolyser designs and engineers patented point-of-care testing equipment and kits, diagnosing a wide range of conditions in animals and humans. Point-of-care testing is done at the time of consultation, leading to the immediate availability of results and more timely, informed decisions concerning treatment. Eurolyser was founded in 2005 and is headquartered in Salzburg, Austria.

Buy -
Mergr

Product

Company

Legal